", "name_5": "surname:Fernandez;given-names:M.", "name_6": "surname:Zuo;given-names:P.", "pub-id_doi": "10.1210/jc.2010-2146", "pub-id_pmid": "21411546", "section_type": "REF", "source": "J. Clin. Endocrinol. Metab.", "type": "ref", "volume": "96", "year": "2011"}, "text": "Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects", "sentences": [], "annotations": [], "relations": []}, {"offset": 47451, "infons": {"fpage": "399", "lpage": "408", "name_0": "surname:Armstrong;given-names:M.J.", "name_1": "surname:Hull;given-names:D.", "name_2": "surname:Guo;given-names:K.", "name_3": "surname:Barton;given-names:D.", "name_4": "surname:Hazlehurst;given-names:J.M.", "name_5": "surname:Gathercole;given-names:L.L.", "name_6": "surname:Nasiri;given-names:M.", "name_7": "surname:Yu;given-names:J.", "name_8": "surname:Gough;given-names:S.C.", "name_9": "surname:Newsome;given-names:P.N.", "pub-id_doi": "10.1016/j.jhep.2015.08.038", "pub-id_pmid": "26394161", "section_type": "REF", "source": "J. Hepatol.", "type": "ref", "volume": "64", "year": "2016"}, "text": "Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis", "sentences": [], "annotations": [], "relations": []}, {"offset": 47531, "infons": {"fpage": "387", "lpage": "405", "name_0": "surname:Scheen;given-names:A.", "pub-id_doi": "10.1080/14740338.2018.1444027", "pub-id_pmid": "29468916", "section_type": "REF", "source": "Expert Opin. Drug Saf.", "type": "ref", "volume": "17", "year": "2018"}, "text": "The safety of gliptins: Updated data in 2018", "sentences": [], "annotations": [], "relations": []}, {"offset": 47576, "infons": {"fpage": "1630", "lpage": "1634", "name_0": "surname:Cusi;given-names:K.", "name_1": "surname:Sanyal;given-names:A.J.", "name_2": "surname:Zhang;given-names:S.", "name_3": "surname:Hartman;given-names:M.L.", "name_4": "surname:Bue-Valleskey;given-names:J.M.", "name_5": "surname:Hoogwerf;given-names:B.J.", "name_6": "surname:Haupt;given-names:A.", "pub-id_doi": "10.1111/dom.12973", "pub-id_pmid": "28417532", "section_type": "REF", "source": "Diabetes Obes. Metab.", "type": "ref", "volume": "19", "year": "2017"}, "text": "Nonalcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes", "sentences": [], "annotations": [], "relations": []}, {"offset": 47712, "infons": {"fpage": "465", "lpage": "483", "name_0": "surname:Andreux;given-names:P.A.", "name_1": "surname:Houtkooper;given-names:R.H.", "name_2": "surname:Auwerx;given-names:J.", "pub-id_doi": "10.1038/nrd4023", "pub-id_pmid": "23666487", "section_type": "REF", "source": "Nat. Rev. Drug Discov.", "type": "ref", "volume": "12", "year": "2013"}, "text": "Pharmacological approaches to restore mitochondrial function. Review", "sentences": [], "annotations": [], "relations": []}, {"offset": 47781, "infons": {"file": "biomedicines-10-00331-g001.jpg", "id": "biomedicines-10-00331-f001", "section_type": "FIG", "type": "fig_caption"}, "text": "(a) Sodium-glucose co-transporter type 2 (SGLT2) inhibitor pathway. (b) Sodium-glucose co-transporter type 2 (SGLT2) inhibitor pathway.", "sentences": [], "annotations": [], "relations": []}, {"offset": 47917, "infons": {"file": "biomedicines-10-00331-g002.jpg", "id": "biomedicines-10-00331-f002", "section_type": "FIG", "type": "fig_caption"}, "text": "Timeline of t2DM Drug Development.", "sentences": [], "annotations": [], "relations": []}, {"offset": 47952, "infons": {"file": "biomedicines-10-00331-t001.xml", "id": "biomedicines-10-00331-t001", "section_type": "TABLE", "type": "table_caption"}, "text": "World diabetes burden by year 2045.", "sentences": [], "annotations": [], "relations": []}, {"offset": 47988, "infons": {"file": "biomedicines-10-00331-t001.xml", "id": "biomedicines-10-00331-t001", "section_type": "TABLE", "type": "table", "xml": "<?xml version=\"1.